Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Oct;63(4):446–451. doi: 10.1136/jnnp.63.4.446

Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis

P Jongen 1, K Lamers 1, W Doesburg 1, W Lemmens 1, O Hommes 1
PMCID: PMC2169777  PMID: 9343121

Abstract

OBJECTIVES—To find whether CSF analysis may differentiate between relapsing-remitting and secondary progressive multiple sclerosis.
METHODS—In 17 patients with relapsing-remitting and 16 patients with secondary progressive multiple sclerosis, all without current or recent relapses, albumin CSF: peripheral blood ratio, mononuclear cell number, CD4+, CD8+, and B1+ subsets, CD4+:CD8+ ratio, IgG, IgG index, IgM, IgM index, complement components C3 and C4, and C3 and C4 indices, myelin basic protein, neuron specific enolase, S100, and lactate were determined. For each measure the statistical distance measure D2 was calculated. For computation of a discriminant score variables with a P value⩽0.15 were included (two sided univariate t test). These were albumin CSF: peripheral blood ratio, mononuclear cell number, IgM, IgM index, C3, C4, neuron specific enolase, S100, and lactate. Simultaneous distributions of the variables were compared between both groups (multivariate t test) and a discriminant score was computed (linear discriminant analysis).
RESULTS—The discriminant score allocated all 14 relapsing-remitting patients to the relapsing-remitting group (positive score) and 12 of 13 secondary progressive patients to the secondary progressive group (negative score). One secondary progressive patient was allocated to the relapsing-remitting group.
CONCLUSIONS—Patients with relapsing-remitting or secondary progressive multiple sclerosis differ in CSF profile and CSF analysis may help to differentiate between relapsing-remitting and secondary progressive multiple sclerosis.



Full Text

The Full Text of this article is available as a PDF (134.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C. M., Lee V. M. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):649–652. doi: 10.1002/ana.410380414. [DOI] [PubMed] [Google Scholar]
  2. Barnes D., Munro P. M., Youl B. D., Prineas J. W., McDonald W. I. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain. 1991 Jun;114(Pt 3):1271–1280. doi: 10.1093/brain/114.3.1271. [DOI] [PubMed] [Google Scholar]
  3. Bornstein M. B., Miller A., Slagle S., Weitzman M., Drexler E., Keilson M., Spada V., Weiss W., Appel S., Rolak L. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991 Apr;41(4):533–539. doi: 10.1212/wnl.41.4.533. [DOI] [PubMed] [Google Scholar]
  4. Cohen S. R., Brooks B. R., Herndon R. M., McKhann G. M. A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid. Ann Neurol. 1980 Jul;8(1):25–31. doi: 10.1002/ana.410080104. [DOI] [PubMed] [Google Scholar]
  5. Cohen S. R., Herndon R. M., McKhann G. M. Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination. N Engl J Med. 1976 Dec 23;295(26):1455–1457. doi: 10.1056/NEJM197612232952604. [DOI] [PubMed] [Google Scholar]
  6. Compston A. Remyelination of the central nervous system. Mult Scler. 1996 Jul;1(6):388–392. doi: 10.1177/135245859600100622. [DOI] [PubMed] [Google Scholar]
  7. Dux R., Kindler-Röhrborn A., Lennartz K., Rajewsky M. F. Calibration of fluorescence intensities to quantify antibody binding surface determinants of cell subpopulations by flow cytometry. Cytometry. 1991;12(5):422–428. doi: 10.1002/cyto.990120507. [DOI] [PubMed] [Google Scholar]
  8. Forsberg P., Henriksson A., Link H., Ohman S. Reference values for CSF-IgM, CSF-IgM/S-IgM ratio and IgM index, and its application to patients with multiple sclerosis and aseptic meningoencephalitis. Scand J Clin Lab Invest. 1984 Feb;44(1):7–12. doi: 10.3109/00365518409083780. [DOI] [PubMed] [Google Scholar]
  9. Franciotta D., Dondi E., Bergamaschi R., Piccolo G., d'Eril G. V., Cosi V., Cuccia M. HLA complement gene polymorphisms in multiple sclerosis. A study on 80 Italian patients. J Neurol. 1995 Jan;242(2):64–68. doi: 10.1007/BF00887817. [DOI] [PubMed] [Google Scholar]
  10. Frequin S. T., Barkhof F., Lamers K. J., Hommes O. R., Borm G. F. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand. 1992 Sep;86(3):291–297. doi: 10.1111/j.1600-0404.1992.tb05088.x. [DOI] [PubMed] [Google Scholar]
  11. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268–1276. doi: 10.1212/wnl.45.7.1268. [DOI] [PubMed] [Google Scholar]
  12. Jongen P. J., Boerbooms A. M., Lamers K. J., Raes B. C., Vierwinden G. Diffuse CNS involvement in systemic lupus erythematosus: intrathecal synthesis of the 4th component of complement. Neurology. 1990 Oct;40(10):1593–1596. doi: 10.1212/wnl.40.10.1593. [DOI] [PubMed] [Google Scholar]
  13. Jongen P. J., Daelmans H. E., Bruneel B., den Hartog M. R. Humoral and cellular immunologic study of cerebrospinal fluid in a patient with Behçet encephalitis. Arch Neurol. 1992 Oct;49(10):1075–1078. doi: 10.1001/archneur.1992.00530340101024. [DOI] [PubMed] [Google Scholar]
  14. KUWERT E., PETTE E., FIRNHABER W., MAI K. DEMONSTRATION OF COMPLEMENT IN SPINAL FLUID IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:429–438. doi: 10.1111/j.1749-6632.1965.tb20225.x. [DOI] [PubMed] [Google Scholar]
  15. Keene O. N. The log transformation is special. Stat Med. 1995 Apr 30;14(8):811–819. doi: 10.1002/sim.4780140810. [DOI] [PubMed] [Google Scholar]
  16. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  17. Lamers K. J., Schoonderwaldt H. C., Borkent M. V., Theeuwes A. G., Doesburg W. H., Wevers R. A. The effects of acute cerebrovascular disease on serum and cerebrospinal fluid parameters. Clin Neurol Neurosurg. 1987;89(1):23–29. doi: 10.1016/s0303-8467(87)80071-9. [DOI] [PubMed] [Google Scholar]
  18. Lamers K. J., van Engelen B. G., Gabreëls F. J., Hommes O. R., Borm G. F., Wevers R. A. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand. 1995 Sep;92(3):247–251. doi: 10.1111/j.1600-0404.1995.tb01696.x. [DOI] [PubMed] [Google Scholar]
  19. Lassmann H., Suchanek G., Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S42–S46. doi: 10.1002/ana.410360713. [DOI] [PubMed] [Google Scholar]
  20. Lolli F., Halawa I., Link H. Intrathecal synthesis of IgG, IgA, IgM and IgD in untreated multiple sclerosis and controls. Acta Neurol Scand. 1989 Sep;80(3):238–247. doi: 10.1111/j.1600-0404.1989.tb03869.x. [DOI] [PubMed] [Google Scholar]
  21. Lublin F. D., Reingold S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr;46(4):907–911. doi: 10.1212/wnl.46.4.907. [DOI] [PubMed] [Google Scholar]
  22. Massaro A. R., Michetti F., Laudisio A., Bergonzi P. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital J Neurol Sci. 1985 Mar;6(1):53–56. doi: 10.1007/BF02229218. [DOI] [PubMed] [Google Scholar]
  23. McLean B. N., Zeman A. Z., Barnes D., Thompson E. J. Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993 Apr;56(4):356–360. doi: 10.1136/jnnp.56.4.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Minderhoud J. M. On the pathogenesis of multiple sclerosis. A revised model of the cause(s) of multiple sclerosis, especially based on epidemiological data. Clin Neurol Neurosurg. 1994 May;96(2):135–142. doi: 10.1016/0303-8467(94)90047-7. [DOI] [PubMed] [Google Scholar]
  25. Mokuno K., Kato K., Kawai K., Matsuoka Y., Yanagi T., Sobue I. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci. 1983 Aug-Sep;60(3):443–451. doi: 10.1016/0022-510x(83)90155-7. [DOI] [PubMed] [Google Scholar]
  26. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):643–648. doi: 10.1002/ana.410380413. [DOI] [PubMed] [Google Scholar]
  27. Persson L., Hårdemark H. G., Gustafsson J., Rundström G., Mendel-Hartvig I., Esscher T., Påhlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke. 1987 Sep-Oct;18(5):911–918. doi: 10.1161/01.str.18.5.911. [DOI] [PubMed] [Google Scholar]
  28. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  29. Prosiegel M., Neu I. S., Pelka R. B., Fateh-Moghadam A. Multivariate analysis of the serum-cerebrospinal fluid-protein-relation for the diagnosis of neurological diseases of the central nervous systems. Acta Neurol Scand. 1983 Dec;68(6):405–412. doi: 10.1111/j.1600-0404.1983.tb04850.x. [DOI] [PubMed] [Google Scholar]
  30. Schuller E., Gervais A., Reboul J., Lebon P., Devillechabrolle A., Huraux J. M. Intrathecal synthesis of proteins: from immunoglobulins to prealbumin. Ital J Neurol Sci. 1992 Dec;13(9 Suppl 14):69–77. [PubMed] [Google Scholar]
  31. Sindic C. J., Cambiaso C. L., Depré A., Laterre E. C., Masson P. L. The concentration of IgM in the cerebrospinal fluid of neurological patients. J Neurol Sci. 1982 Sep;55(3):339–350. doi: 10.1016/0022-510x(82)90131-9. [DOI] [PubMed] [Google Scholar]
  32. Sindic C. J., Chalon M. P., Cambiaso C. L., Laterre E. C., Masson P. L. Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 1982 Dec;45(12):1130–1135. doi: 10.1136/jnnp.45.12.1130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sinnige L. G., Teeuwissen E., Hew J. M., Minderhoud J. M. Correlation between magnetic resonance imaging and clinical parameters in multiple sclerosis. Acta Neurol Scand. 1995 Mar;91(3):188–191. doi: 10.1111/j.1600-0404.1995.tb00431.x. [DOI] [PubMed] [Google Scholar]
  34. Sipe J. C., Knobler R. L., Braheny S. L., Rice G. P., Panitch H. S., Oldstone M. B. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology. 1984 Oct;34(10):1368–1372. doi: 10.1212/wnl.34.10.1368. [DOI] [PubMed] [Google Scholar]
  35. Traugott U., Reinherz E. L., Raine C. S. Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol. 1983 Jun;4(3):201–221. doi: 10.1016/0165-5728(83)90036-x. [DOI] [PubMed] [Google Scholar]
  36. Uitdehaag B. M., Nillesen W. M., Hommes O. R. Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol Scand. 1989 Jan;79(1):12–17. doi: 10.1111/j.1600-0404.1989.tb03702.x. [DOI] [PubMed] [Google Scholar]
  37. van Engelen B. G., Lamers K. J., Gabreels F. J., Wevers R. A., van Geel W. J., Borm G. F. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem. 1992 Jun;38(6):813–816. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES